Savara: A High-Risk Opportunity [Seeking Alpha]
Savara, Inc. (SVRA)
Last savara, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
savarapharma.com/investors/events-presentations
Company Research
Source: Seeking Alpha
Molgramostim showed strong DLCO results in IMPALA-2, with a notable reduction in whole lung lavage need, addressing a $2B+ U.S. market. SVRA holds $125M+ in cash, recently raised $140M, and analysts unanimously rate it a buy, projecting $400M in 2030 sales. An analysis around Savara, Inc. follows in the paragraphs below. da-kuk/E+ via Getty Images Shares of respiratory disease concern Savara, Inc. ( SVRA have rebounded over 100% since receiving a refuse-to-file letter from the FDA for its sole clinical candidate (molgramostim) in May 2025. The rebound is largely due to the company's alignment with More on my IG service Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE This article was written by Analyst's Disclosure: I/we have no stock, option or
Show less
Read more
Impact Snapshot
Event Time:
SVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SVRA alerts
High impacting Savara, Inc. news events
Weekly update
A roundup of the hottest topics
SVRA
News
- Savara Inc. ticks higher amid takeover speculation [Seeking Alpha]Seeking Alpha
- Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer SystemBusiness Wire
- Savara Announces Participation in Upcoming Investor Healthcare ConferencesBusiness Wire
- Savara (NASDAQ:SVRA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $8.00 to $9.00. They now have an "outperform" rating on the stock.MarketBeat
- Savara (NASDAQ:SVRA) had its price target lowered by analysts at Citizens Jmp from $11.00 to $10.00. They now have a "market outperform" rating on the stock.MarketBeat
SVRA
Earnings
- 11/12/25 - Miss
SVRA
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- 11/17/25 - Form 4
- SVRA's page on the SEC website